We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Akram A.
Hosseini
ahosseini@doctors.org.uk
Dr
Akram A.
Hosseini
ahosseini@doctors.org.uk
Provisional assignment of new diseases of uncertain etiologyOther degenerative diseases of the nervous systemOrganic, including symptomatic, mental disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
We aim to determine whether changes in brain structure, function and connectivity are influenced by the underlying disease, whether imaging can be used to accurately differentiate between subtypes, and whether features on imaging can be used to predict long term consequences of COVID-19 on cognition (thinking ability).
We will use cutting edge brain scanning technology, magnetic resonance imaging (MRI) to measure what goes wrong in different parts of the brain and the way groups of cells are damaged. We will link these changes to patients’ symptoms, examinations and their neuropsychological assessment scores. In addition, we study the markers, proteins and immunological reactions in the blood in relation to the findings on the MRI of the head. Since there is increasing appreciation of the importance of genes in determining diseases, we will also study the genes that can increase the risk of developing Alzheimer’s disease or different dementia subtypes. The genes that we study are not proven to reliably predict developing future dementia and we study the risks of carrying the genes in relation to the changes on the MRI of the head and other immunological markers in the blood and susceptibility to COVID-19. In order to do the gene tests, we will isolate from blood the chemical that contains the genetic code and that is called DNA.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Imaging;
You can take part if:
You may not be able to take part if:
COVID cases: 1) Contraindication to 7T MRI scans 2) Unable to provide informed consent for themselves as assessed by consent comprehension tool. 3) Unwilling/unable to travel to a site where the 7T MRIs are performed. 4) Pre-existing medical, psychiatric, or neurological illness that, in the opinion of the PI, would confound the results of study testing. Control-illness group: 1) Contraindication to 7T MRI scans 2) Unable to provide informed consent for themselves as assessed by consent comprehension tool. 3) Unwilling/unable to travel to a site where the 7T MRIs are performed. 4) Pre-existing medical, psychiatric, or neurological illness that, in the opinion of the PI, would confound the results of study testing. Control-healthy group: 1) Contraindication to 7T MRI scans. 2) Unable to provide informed consent for themselves as assessed by consent comprehension tool. 3) Unwilling/unable to travel to a site where the 7T MRIs are performed. 4) Pre-existing medical, psychiatric, or neurological illness that, in the opinion of the PI, would confound the results of study testing.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST and funded by National Institutes of Health (NIH), United States .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 52579
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
